vs
Inspirato Inc（ISPO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Inspirato Inc的季度营收约是REGENXBIO Inc.的1.8倍（$55.5M vs $30.3M），Inspirato Inc净利率更高（-8.1% vs -221.3%，领先213.2%），REGENXBIO Inc.同比增速更快（43.0% vs -19.6%），Inspirato Inc自由现金流更多（$-3.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -11.4%）
Inspirato Inc是一家高端旅行及酒店订阅服务供应商，主要面向北美高净值人群，提供精选豪华别墅租赁、专属度假村权益、定制化行程规划服务，同时也为企业客户提供高端员工差旅激励解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ISPO vs RGNX — 直观对比
营收规模更大
ISPO
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出62.6%
-19.6%
净利率更高
ISPO
高出213.2%
-221.3%
自由现金流更多
ISPO
多$49.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-11.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.5M | $30.3M |
| 净利润 | $-4.5M | $-67.1M |
| 毛利率 | 31.4% | — |
| 营业利润率 | -8.0% | -190.0% |
| 净利率 | -8.1% | -221.3% |
| 营收同比 | -19.6% | 43.0% |
| 净利润同比 | -204.4% | -31.2% |
| 每股收益（稀释后） | $-0.36 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISPORGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | $55.5M | $29.7M | ||
| Q2 25 | $63.1M | $21.4M | ||
| Q1 25 | $65.9M | $89.0M | ||
| Q4 24 | $63.1M | $21.2M | ||
| Q3 24 | $69.1M | $24.2M | ||
| Q2 24 | $67.4M | $22.3M | ||
| Q1 24 | $80.2M | $15.6M |
净利润ISPORGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-4.5M | $-61.9M | ||
| Q2 25 | $-5.3M | $-70.9M | ||
| Q1 25 | $1.6M | $6.1M | ||
| Q4 24 | $-2.3M | $-51.2M | ||
| Q3 24 | $4.3M | $-59.6M | ||
| Q2 24 | $-8.7M | $-53.0M | ||
| Q1 24 | $1.3M | $-63.3M |
毛利率ISPORGNX
| Q4 25 | — | — | ||
| Q3 25 | 31.4% | — | ||
| Q2 25 | 27.5% | — | ||
| Q1 25 | 38.8% | — | ||
| Q4 24 | 34.7% | 70.2% | ||
| Q3 24 | 71.5% | 48.8% | ||
| Q2 24 | 24.0% | 52.5% | ||
| Q1 24 | 39.5% | 72.6% |
营业利润率ISPORGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | -8.0% | -176.3% | ||
| Q2 25 | -8.3% | -296.3% | ||
| Q1 25 | 2.5% | 13.6% | ||
| Q4 24 | -3.2% | -242.1% | ||
| Q3 24 | 9.8% | -256.6% | ||
| Q2 24 | -22.8% | -251.3% | ||
| Q1 24 | 3.0% | -408.8% |
净利率ISPORGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -8.1% | -208.3% | ||
| Q2 25 | -8.4% | -331.8% | ||
| Q1 25 | 2.5% | 6.8% | ||
| Q4 24 | -3.6% | -241.3% | ||
| Q3 24 | 6.3% | -246.3% | ||
| Q2 24 | -12.9% | -237.7% | ||
| Q1 24 | 1.6% | -405.4% |
每股收益（稀释后）ISPORGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $-0.36 | $-1.20 | ||
| Q2 25 | $-0.42 | $-1.38 | ||
| Q1 25 | $0.12 | $0.12 | ||
| Q4 24 | $0.98 | $-0.99 | ||
| Q3 24 | $0.62 | $-1.17 | ||
| Q2 24 | $-2.33 | $-1.05 | ||
| Q1 24 | $-0.18 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-134.0M | $102.7M |
| 总资产 | $228.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ISPORGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $13.7M | $274.2M | ||
| Q2 25 | $16.7M | $323.3M | ||
| Q1 25 | $16.4M | $267.9M | ||
| Q4 24 | $21.8M | $234.7M | ||
| Q3 24 | $13.5M | $255.5M | ||
| Q2 24 | $18.8M | $290.4M | ||
| Q1 24 | $22.6M | $338.7M |
股东权益ISPORGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | $-134.0M | $161.5M | ||
| Q2 25 | $-129.7M | $213.7M | ||
| Q1 25 | $-125.2M | $274.2M | ||
| Q4 24 | $-129.9M | $259.7M | ||
| Q3 24 | $-134.6M | $301.4M | ||
| Q2 24 | $-35.2M | $348.3M | ||
| Q1 24 | $-27.5M | $390.7M |
总资产ISPORGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | $228.3M | $525.2M | ||
| Q2 25 | $252.6M | $581.0M | ||
| Q1 25 | $270.1M | $490.9M | ||
| Q4 24 | $273.9M | $466.0M | ||
| Q3 24 | $273.3M | $519.1M | ||
| Q2 24 | $301.7M | $569.4M | ||
| Q1 24 | $313.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -5.4% | -174.0% |
| 资本支出强度资本支出/营收 | 1.4% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-31.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ISPORGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $-2.2M | $-56.0M | ||
| Q2 25 | $1.1M | $-49.3M | ||
| Q1 25 | $-6.6M | $33.6M | ||
| Q4 24 | $-15.8M | $-31.6M | ||
| Q3 24 | $-13.7M | $-40.5M | ||
| Q2 24 | $-1.8M | $-45.5M | ||
| Q1 24 | $-7.2M | $-55.5M |
自由现金流ISPORGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $-3.0M | $-56.5M | ||
| Q2 25 | $468.0K | $-49.7M | ||
| Q1 25 | $-7.5M | $32.6M | ||
| Q4 24 | $-21.2M | $-32.7M | ||
| Q3 24 | $-14.8M | $-40.9M | ||
| Q2 24 | $-3.7M | $-46.0M | ||
| Q1 24 | $-8.5M | $-56.0M |
自由现金流率ISPORGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | -5.4% | -189.9% | ||
| Q2 25 | 0.7% | -232.8% | ||
| Q1 25 | -11.4% | 36.6% | ||
| Q4 24 | -33.7% | -154.2% | ||
| Q3 24 | -21.5% | -168.9% | ||
| Q2 24 | -5.5% | -206.2% | ||
| Q1 24 | -10.6% | -358.5% |
资本支出强度ISPORGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 8.7% | 5.1% | ||
| Q3 24 | 1.6% | 1.3% | ||
| Q2 24 | 2.8% | 2.1% | ||
| Q1 24 | 1.6% | 3.6% |
现金转化率ISPORGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -4.09× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -3.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -5.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISPO
| Residence And Hotel Travel | $25.9M | 47% |
| Subscription | $19.4M | 35% |
| Experiences And Bespoke Travel | $8.0M | 14% |
| Rewards And Other Revenue | $2.3M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
